Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. The company has a portfolio of clinical-stage product candidates targeting pain and immuno-inflammatory diseases. It has two subsidiaries: Zalicus Pharmaceuticals Ltd. and Zalicus Securities Corp. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA.